Ann: Update on licensing Progenza in Japan, page-2

So now all shareholders are belatedly in the picture and not second guessing what might be happening, or might have happened with the Japanese licensing negotiations.

It beats me why the company couldn't have released this announcement before the end of the FY when it had become apparent (to Regeneus) that a clinical licensing partner in Japan for Progenza would not be achieved within the company's expected timeframe. It's just good corporate communications practice 101.

zeno9